Patent FR-2866031-A1 (FR)
Title: Viral chimer, useful to e.g. treat viral diseases, comprises capsid and/or lipidic envelop, defective genome, genome to serve a helper virus and genome comprising nucleotide sequences encoding polypeptides used in viral antigenicity
Inventor: MILLET DAVID FRANCOIS JOSEPH
IPC: A61K39/12
Filed: 2004-02-11
Abstract: Viral chimer (I) comprising a capsid and/or a lipidic envelop integrating the constituents of viral pathogen, a defective genome phylogenically close to the viral pathogen obtained from genetic construction, a genome having the capacity to serve a helper virus in vivoor ex vivo, and a genome comprising nucleotidic sequences encoding for polypeptides implied in the antigenicity of virus, is new. Viral chimer (I) comprises: (a) a capsid and/or a lipidic envelop integrating the constituents of a viral pathogen responsible for the specific recognition of membrane receptors of cells infected by the virus, and also all the other viral constituents of viral pathogen necessary for the penetration of viral pathogen genome in the infected cells; (b) a defective genome phylogenically close to one of the viral pathogen, obtained from genetic construction, which makes the single chimer incapable, after penetration in the target cells, to generate the intracellular synthesis of polypeptides obtained from its genome; (c) a genome obtained from genetic construction so that the viral pathogen has the capacity to serve helper virus in vivoor ex vivofor the chimer and the presence of pathogen virus catalyze the intracellular synthesis obtained from the genome of the chimer, and the same cells are co-infected by the pathogen virus and the chimer; and (d) a genome from a genetic construction comprising one or more nucleotidic sequences encoding for one or more polypeptides implied in the antigenicity of viral pathogen, in which the polypeptides contain one or more epitopes identical to those against which one or more known vaccines direct the immunity. Independent claims are also included for: (1) a pharmaceutical composition (II) useful in the prophylaxis or treatment of viral diseases or influenza A virus comprising (I) and optionally an additive, a diluent, an excipient and/or a vehicle; (2) detecting and/or quantifying a viral infection comprising detecting a previously detected human or animal biological sample in humans/animals that are previously vaccinated with the vaccine and previously received the administration of a composition in which the antibody directed against the coded antigens by the genome of the chimers and optionally the antibodies of are quantified with respect to a concentration of reference; and (3) a chimeric influenza A virus comprising proteins of envelop M 2, HA and NA having little or no circulation within a human population and not generating a weak immune reaction, in vivo when administering within the population; proteins PA and/or NP and/or PB 1and/or PB 2, of which the sequences of amino acids were modified in such a manner that the RNA viral polymerase constitutive of cRNP of the chimeric virus with lost properties of catalysing mRNA or synthesis of these mRNA is negligible but having conserved its properties of replication of genome and a genome comprising combinations of (I). ACTIVITY : Virucide. No biological data is given. MECHANISM OF ACTION : Vaccine.